paraneoplastic syndrome
paraneoplastic syndrome
Explore linked clinical trials. Standard reference: MONDO:0021073180 results · Page 1 of 8
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 3 | 2026-10-09 | NCT07463521 | |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06359041 | |
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | ACTH-dependent Cushing syndrome, Cushing syndrome, Neoplasms by Histologic Type, Neoplasms by Site, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, adrenal gland hyperfunction, brain disorder, carcinoma, cardiovascular disorder, central nervous system disorder, diabetes mellitus, ectopic ACTH secretion syndrome, endocrine system disorder, epithelial neoplasm, glucose metabolism disease, hyperpituitarism, hypertensive disorder, hypothalamic disorder, malignant endocrine neoplasm, metabolic disease, neoplasm, nervous system disorder, paraneoplastic syndrome, pituitary gland disorder, type 2 diabetes mellitus, vascular disorder | Active, not recruiting | Phase 2 | 2026-10-09 | NCT03604198 | |
| A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 3 | 2026-10-08 | NCT07465289 | |
| Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks | Bone Diseases, Metabolic, Neoplasms by Site, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, adrenal gland cancer, adrenal gland disorder, adrenal gland hyperfunction, bone disorder, cardiovascular disorder, ectopic ACTH secretion syndrome, endocrine system disorder, glucose metabolism disease, hyperaldosteronism, hyperinsulinism, hypertensive disorder, malignant endocrine neoplasm, metabolic disease, musculoskeletal system disorder, neoplasm, paraneoplastic syndrome, vascular disorder | Recruiting | Not stated | 2026-10-08 | NCT03374215 | |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Cushing syndrome, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, adrenal gland disorder, adrenal gland hyperfunction, diabetes mellitus, ectopic ACTH secretion syndrome, endocrine system disorder, glucose metabolism disease, metabolic disease, neoplasm, paraneoplastic syndrome, type 2 diabetes mellitus | Recruiting | Phase 2 | 2026-10-06 | NCT07296484 | |
| Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies | Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, anti-NMDA receptor encephalitis, autoimmune disease, autoimmune disorder of the nervous system, autoimmune encephalitis, brain disorder, central nervous system disorder, encephalitis, immune system disorder, neoplasm, nervous system disorder, neurodegenerative disease, paraneoplastic syndrome | Not yet recruiting | Not stated | 2026-10-05 | NCT07858175 | |
| Feasibility of Remote Monitoring of Patients With Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Not stated | 2026-10-05 | NCT07787247 | |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 2 | 2026-10-05 | NCT06987539 | |
| An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Enrolling by invitation | Phase 3 | 2026-10-02 | NCT06435312 | |
| A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 2 / Phase 3 | 2026-10-02 | NCT06055959 | |
| Incidence and Predictors of Early Clinical Relapse Within Six Months After Thymectomy in Patients With Myasthenia Gravis | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Thoracic Neoplasms, Thymus Neoplasms, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, lymphatic system disorder, mixed neoplasm, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome, thymoma | Not yet recruiting | Not stated | 2026-10-01 | NCT07853378 | |
| A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06744920 | |
| A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 2 / Phase 3 | 2026-09-28 | NCT06392386 | |
| A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) | Myasthenia Gravis, Generalized, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 3 | 2026-09-25 | NCT07647510 | |
| Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 3 | 2026-09-25 | NCT07217587 | |
| Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cushing syndrome, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, Urogenital Abnormalities, Urogenital Diseases, adrenal gland disorder, adrenal gland hyperfunction, adrenogenital syndrome, congenital adrenal hyperplasia, disorder of sexual differentiation, ectopic ACTH secretion syndrome, endocrine system disorder, gonadal disorder, hereditary disease, inborn errors of metabolism, metabolic disease, neoplasm, paraneoplastic syndrome, steroid inherited metabolic disorder | Recruiting | Phase 2 | 2026-09-25 | NCT07138274 | |
| A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-25 | NCT06149559 | |
| Metyrapone for Mild Autonomous Cortisol Secretion (MACS) | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cushing syndrome, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, Urogenital Abnormalities, Urogenital Diseases, adrenal gland disorder, adrenal gland hyperfunction, adrenogenital syndrome, congenital adrenal hyperplasia, disorder of sexual differentiation, ectopic ACTH secretion syndrome, endocrine system disorder, gonadal disorder, hereditary disease, inborn errors of metabolism, metabolic disease, neoplasm, paraneoplastic syndrome, steroid inherited metabolic disorder | Active, not recruiting | Phase 2 | 2026-09-25 | NCT06106295 | |
| ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, generalized myasthenia gravis, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 2 | 2026-09-24 | NCT07673627 | |
| ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, generalized myasthenia gravis, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Not stated | 2026-09-24 | NCT07294170 | |
| ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, generalized myasthenia gravis, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 2 | 2026-09-24 | NCT07284420 | |
| Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) | CNS demyelinating autoimmune disease, Infections, Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, central nervous system disorder, central nervous system infectious disorder, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, myelitis, neoplasm, nervous system disorder, neurodegenerative disease, optic nerve disorder, optic neuritis, paraneoplastic syndrome, spinal cord disorder | Recruiting | Phase 3 | 2026-09-24 | NCT07100990 | |
| A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 2 | 2026-09-22 | NCT07673744 | |
| A Study in Patients With Myasthenia Gravis in China | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Not stated | 2026-09-18 | NCT06700616 |